The benefits of clopidogrel in the treatment and prevention of coronary artery disease vary among patients. Studies have identified predictive markers of poor response to clopidogrel that might allow risk stratification of patients. Are we ready to enter the age of personalized medicine?
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Smith, S. C. Jr et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 Update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113, 2363–2372 (2006).
Serebruany, V. L. et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J. Am. Coll. Cardiol. 45, 246–251 (2005).
Snoep, J. D. et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J. 154, 221–231 (2007).
Paniccia, R. et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J. Thromb. Haemost. 5, 1839–1847 (2007).
Marcucci, R. et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119, 237–242 (2009).
Price, M. J. et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur. Heart J. 29, 992–1000 (2008).
Patti, G. et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA–PRO (Antiplatelet Therapy for Reduction of Myocardial Damage during Angioplasty–Platelet Reactivity Predicts Outcome) study. J. Am. Coll. Cardiol. 52, 1128–1133 (2008).
Deeks, J. J. & Altman, D. G. Diagnostic tests 4: Likelihood ratios. BMJ 329, 168–169 (2004).
Mega, J. L. et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354–362 (2009).
Collet, J. P. et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373, 309–317 (2009).
Geisler, T. et al. CYP2C19 and nongenetic factors predict poor reponsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 9, 1251–1259 (2008).
The authors declare no competing financial interests.
About this article
Cite this article
Hulot, JS., Fuster, V. Personalized medicine for clopidogrel resistance?. Nat Rev Cardiol 6, 334–336 (2009). https://doi.org/10.1038/nrcardio.2009.28
This article is cited by
Nature Reviews Cardiology (2011)
Nature Reviews Cardiology (2009)